Radiation Oncology Department, Centre Paul Strauss 3 rue de la Porte de l'hôpital, 67065, Strasbourg Cedex, France.
Radiation Oncology Department, Centre Paul Strauss 3 rue de la Porte de l'hôpital, 67065, Strasbourg Cedex, France; Radiobiology Laboratory, EA3430, Strasbourg University, 3 rue de la Porte de l'hôpital, 67000, Strasbourg, France.
Crit Rev Oncol Hematol. 2018 Mar;123:138-148. doi: 10.1016/j.critrevonc.2018.01.011. Epub 2018 Feb 8.
Hematologic malignancies may require, at one point during their treatment, allogeneic bone marrow transplantation. Total body irradiation combined with chemotherapy or radiomimetic used in allogeneic bone marrow transplantation is known to be very toxic. Total body irradiation (TBI) induces immunosuppression to prevent the rejection of donor marrow. TBI is also used to eradicate malignant cells and is in sanctuary organs that are not reached by chemotherapy drugs. TBI has evolved since its introduction in the late fifties, but acute and late toxicities remain. Helical tomotherapy, which is widely used for some solid tumors, is a path for the improvement of outcomes and toxicities in TBI because of its sparing capacities. In this article, we first review the practical aspects of TBI with patient positioning, radiobiological considerations and total dose and fractionation prescriptions. Second, we review the use of intensity modulated radiation therapy in bone marrow transplantation with a focus on helical tomotherapy TBI, helical tomotherapy total marrow irradiation (TMI) and total marrow and lymphoid irradiation (TMLI) and their dosimetric and clinical outcomes. Finally, we review the perspective of dose escalation and the extension to older patients and patients with comorbidity who do not benefit from a standard bone marrow transplantation conditioning regimen.
血液系统恶性肿瘤在治疗过程中,可能需要异体骨髓移植。全身照射(TBI)联合化疗或放射模拟药物用于异体骨髓移植,已知具有很强的毒性。全身照射(TBI)可诱导免疫抑制,以防止供体骨髓排斥。TBI 还用于根除恶性细胞,并在化学药物无法到达的避难器官中发挥作用。自 20 世纪 50 年代末引入以来,TBI 不断发展,但仍存在急性和迟发性毒性。螺旋断层放疗已广泛应用于某些实体肿瘤,由于其具有保护作用,是改善 TBI 结果和毒性的途径。在本文中,我们首先回顾了 TBI 的实际方面,包括患者定位、放射生物学考虑因素以及总剂量和分割处方。其次,我们回顾了调强放疗在骨髓移植中的应用,重点介绍了螺旋断层放疗 TBI、螺旋断层放疗全骨髓照射(TMI)和全骨髓和淋巴照射(TMLI)及其剂量学和临床结果。最后,我们回顾了剂量递增的前景以及对年龄较大的患者和患有不能从标准骨髓移植预处理方案中获益的合并症患者的扩展。